Physician profile
Michael G Buck
NPI 1063402667
$7,088.84
in general payments reported to CMS, 2019-2025
42 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $608 · 2021: $937 · 2022: $1,143 · 2023: $1,614 · 2024: $1,389 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,157.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,852.95 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,031.04 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $754.04 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $539.87 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $492.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $391.67 | 2020-2025 | |
| Amgen INC. | $367.42 | 2019-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $211.90 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.15 | 2019-2024 | Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.34 | 2021-2024 | Xifaxan, Trulance |
| Mannkind Corporation | $118.80 | 2022 | |
| Sanofi-Aventis U.S. LLC | $113.93 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $92.98 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $71.98 | 2023-2025 | Gvoke Hypopen |
| Abbott Laboratories | $61.41 | 2021-2024 | Freestyle Libre 3 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.